Ipamorelin in Mexico: GHRP pentapeptide selective for the ghrelin receptor

EXOMA Scientific Team · Publicado el 24 de mayo de 2026 · Actualizado el 18 de septiembre de 2026

Ipamorelin is a GHRP pentapeptide developed by Novo Nordisk, characterized by its selectivity for GHS-R1a without significant elevation of cortisol or prolactin.

Executive summary

Ipamorelin (Ipamorelin, CAS 170851-70-4, molecular formula C38H49N9O5, molecular weight 711.85 g/mol) is the object of growing interest in preclinical research for its selectivity for GHS-R1a with a pharmacological profile free of significant elevation of cortisol/prolactin. This technical guide brings together molecular characterization, mechanism of action, bibliographic evidence with DOI/PubMed, and handling considerations for research use only.

Regulatory notice. This material is exclusively for in vitro and preclinical research use. It does not constitute a clinical or therapeutic recommendation.

What is Ipamorelin?

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide developed by Novo Nordisk in the 1990s, belonging to the class of Growth Hormone Releasing Peptides (GHRPs). Its sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 confers high affinity and selectivity for the GHS-R1a receptor (ghrelin receptor) expressed in pituitary somatotrophs and the hypothalamic arcuate nucleus.

Key molecular data

Mechanism of action

Unlike GHRP-2 y GHRP-6, la estructura de ipamorelina minimiza la unión cruzada con receptores de melanocortina, lo cual se traduce en una respuesta de GH limpia sin la elevación concomitante de prolactina, ACTH o cortisol observada con otros secretagogos.

The mechanistic characterization available in indexed literature (PubMed, Web of Science) makes it possible to categorize Ipamorelin as an object of research of high interest in its category. The most highly cited publications are reproduced in the section Bibliographic evidence below.

Documented lines of research

The available preclinical literature addresses mainly:

1. Pharmacokinetic characterization: in vivo studies in murine and porcine models on absorption, distribution, metabolism, and excretion of the analog.
2. Receptor mechanisms: competitive binding assays with radioligands to map affinity and selectivity for target receptors.
3. Animal efficacy models: preclinical assays on the phenotypic effect attributable to the peptide in models of the pathology under study.
4. In vitro stability and formulation: evaluation of the chemical and biological stability of the peptide under different storage and reconstitution conditions.

For an up-to-date systematic review, the researcher is advised to consult the PubMed, Google Scholar and Web of Science databases using the terms Ipamorelina and Ipamorelin.

Bibliographic evidence

• Raun K et al., 1998 — Eur J Endocrinol. Initial characterization of ipamorelin as the first selective GH secretagogue without elevation of cortisol/prolactin. PubMed: 9849822
• Sinha DK, Balasubramanian A, Tatem AJ, 2020 — Transl Androl Urol. Beyond the androgen receptor: the role of GH secretagogues in the modern management of body composition. PubMed: 32257855

Handling, reconstitution, and storage

Receipt and verification. Each lyophilized vial of Ipamorelin is shipped with its corresponding certificate of analysis (COA) issued by Chromasys, which includes identity by mass spectrometry, purity by reverse-phase HPLC, peptide content by amino acid analysis, residual acetate/TFA, residual water by Karl Fischer and endotoxins by LAL.

Standard reconstitution (research protocol). The standard procedure for sterile reconstitution is as follows:

1. Disinfect with isopropyl alcohol the rubber stoppers of the lyophilized Ipamorelin vial and of the vial of bacteriostatic water (BAC).
2. Aspirar el volumen calculado de BAC con jeringa de insulina estéril (consultar la EXOMA reconstitution calculator).
3. Inject the solvent slowly, resting the needle against the inner wall of the vial — never directly onto the lyophilized powder, to avoid aggregation and denaturation.
4. Gently roll the vial between your fingers until a clear solution is obtained. Never shake.
5. Store the reconstituted vial refrigerated (2–8 °C) protected from light. Avoid freeze-thaw cycles.

Storage of the lyophilizate. Refrigerated at 2–8 °C protected from light until the retest date indicated in the batch's COA.

Products available at EXOMA

• `/producto/ipamorelin`
• `/producto/ipamorelin`
• `/producto/ipamorelin`

All presentations are shipped with a batch COA and meet the reverse-phase HPLC purity standard. The larger-mass presentation usually offers the lowest cost per milligram.

Logistics and delivery

• Coverage. All of the Mexican Republic via courier with tracking number (AfterShip).
• Transit time. 1-4 business days depending on the region from payment confirmation.
• Shipping cost. $200 MXN de tarifa nacional única; envío gratuito en pedidos desde $2,000 MXN.
• Processing cutoff. Pedidos confirmados antes de las 16:30 (4:30 PM) hora del centro de México de lunes a viernes salen el mismo día hábil.

Additional resources

• Scientific hub: /producto/ipamorelin — variants, comparisons, studies, and full FAQ.
• Compendium: /compendio/ipamorelin — technical sheet with sequence and molecular references.
• Reconstitution calculator: /calculadora.
• Storage guide: /guia-conservacion.

This guide is educational content aimed at researchers. The information does not constitute medical advice or diagnosis. All data are reproduced for technical purposes and to support research-material procurement decisions. Bibliographic references are available on PubMed/DOI for independent verification.

References

Material for research use only. Verified primary sources supporting the scientific claims of this article:

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822. (animal / in vitro)
2. Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, Thøgersen H, Hansen TK, Peschke B, Lau J, Lundt BF, Andersen PH. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J Med Chem. 1998;41(19):3699-3704. doi:10.1021/jm9801962. PMID 9733495. (in vitro / animal)
3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402. PMID 10496658. (human)